Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

NCT01173497 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01173497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01173497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
July 31, 2013
Enrollment
44 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, estrogen receptor negative (er-negative) breast cancer, human epidermal growth factor receptor 2 negative (her2-negative) breast cancer, progesterone receptor negative (pr-negative) breast cancer